Bill Gates and NIH Use GMO Mosquitoes to “Vaccinate” Humans in Malaria Study
Find out why Stew Peters, JD Rucker, and Chuck Norris all agree you should move your wealth or retirement to precious metals ASAP with this America First company.
The National Institutes of Health (NIH) funded a malaria vaccine trial study that used genetically modified (GM) mosquitoes to “vaccinate” humans.
A team of researchers at the University of Washington conducted the study, which was published in the Science Translational Medicine journal.
The study involved 26 participants who received three to five “jabs” — or bites from a small box containing 200 GM mosquitoes — over a 30-day period.
Sanaria, a company funded in part by the Bill & Melinda Gates Foundation (BMGF), is closely connected to the research, and the researchers involved in the trial use a gene-editing technology heavily promoted by Bill Gates.
Former NY Governor Andrew Cuomo didn’t listen to Dr. Zev Zelenko about Covid-19. Don’t be a Cuomo. Dr. Zelenko’s new Z-Dtox and Z-Stack nutraceuticals come highly recommended by many doctors.
Despite the study’s mixed results, the researchers claimed the “results support further development of genetically attenuated sporozoites as potential malaria vaccines.”
The researchers suggested several reasons for using live mosquitoes rather than a vaccine that could be delivered via a syringe, including that the use of live insects made sense, as the P. falciparum parasite quickly matures inside the mosquito.
In addition, the process of developing a version of the parasite that could be delivered via a syringe was described as “costly and time consuming.”
Nevertheless, according to Murphy the study will not be used for the mass vaccination of humans. However, the researchers involved in the trial said they believe the approach they used can eventually result in the development of a “substantially more effective” malaria vaccine.
At present, only one malaria vaccine is in use. The RTS,S vaccine produced by GlaxoSmithKline was approved by the World Health Organization in October 2021, but reportedly has an efficacy rate of only 30-40%.
Dr. Kirsten Lyke, a vaccine researcher at the University of Maryland, described the use of a genetically modified live parasite as a vaccine as “a total game changer,” saying the team of researchers “went old school with this one.”
“All things old become new again,” Lyke told NPR.
Lyke, who was not involved in the GM mosquito malaria trial, led the Phase 1 trials for the Pfizer/BioNTech COVID-19 vaccine and also served as co-investigator for COVID-19 vaccine trials administered by Moderna and Novavax.
Stefan Kappe, a parasitologist at the University of Washington and the Seattle Children’s Research Institute — who was one of the authors of the study — said that the approach described by Lyke is already being worked on by the team, adding that the team believes “we can obviously do better.”
However, according to Kappe, “increasing production capability to scale up manufacturing will require investment.”
The research team said that the vaccine developed from this process will eventually be administered via syringes, in order to administer a “more accurate dosage.”
According to Lyke, the use of a slightly more mature version of the GM parasite used during this trial could better equip the human body to prepare an immune response.
Buy precious metals to protect your wealth. Pick your style: GoldCo offers options. Our Gold Guy has no frills.
Murphy added that his team’s approach utilizes a whole weakened parasite rather than one of the proteins the parasite produces, as with the RTS,S vaccine.